**Product** Data Sheet

# **Screening Libraries**

# **Proteins**

# 1-Deoxynojirimycin

Cat. No.: HY-14860 CAS No.: 19130-96-2 Molecular Formula:  $C_6H_{13}NO_4$ Molecular Weight: 163.17

Target: Glucosidase; PI3K

Pathway: Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Storage: -20°C Powder 3 years

> $4^{\circ}C$ 2 years

-80°C In solvent 2 years

> -20°C 1 year

## **SOLVENT & SOLUBILITY**

In Vitro

 $H_2O : \ge 34 \text{ mg/mL} (208.37 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 6.1286 mL | 30.6429 mL | 61.2858 mL |
|                              | 5 mM                          | 1.2257 mL | 6.1286 mL  | 12.2572 mL |
|                              | 10 mM                         | 0.6129 mL | 3.0643 mL  | 6.1286 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (612.86 mM); Clear solution; Need ultrasonic

# **BIOLOGICAL ACTIVITY**

Description

 $1\hbox{-}Deoxynojirimycin (Duvoglustat) is a potent and orally active $\alpha$-glucosidase inhibitor. \\ 1\hbox{-}Deoxynojirimycin suppresses$ postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, antiobesity, and antiviral features<sup>[1][2]</sup>.

In Vivo

- 1-Deoxynojirimycin (Duvoglustat) (20-80 mg/kg; i.v.; daily for four weeks) shows anti-obesity effect [3].
- ?1-Deoxynojirimycin significantly improves insulin sensitivity via activating insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

db/db mice<sup>[3]</sup> Animal Model:

| Dosage:         | 20, 40, 80 mg/kg   |  |
|-----------------|--|--|
| Administration: | Intravenously; daily for four weeks  |  |
| Result:         | Significantly reduced body weight, blood glucose and serum insulin levels; Improved glucose tolerance and insulin tolerance. |  |

# **CUSTOMER VALIDATION**

- Environ Microbiol. 2021 Mar 15.
- J Biol Chem. 2023 Sep 1;105211.
- Exp Cell Res. 2020 Nov 2;397(1):112334.

See more customer validations on www.MedChemExpress.com

# **REFERENCES**

[1]. Chaluntorn Vichasilp, et al. Development of high 1-deoxynojirimycin (DNJ) content mulberry tea and use of response surface methodology to optimize tea-making conditions for highest DNJ extraction. LWT - Food Science and Technology. Volume 45, Issue 2, March 2012, Pages 226-232

[2]. Gao K, et al. 1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and In Silico Target Fishing. Molecules. 2016 Nov 23;21(11). pii: E1600.

[3]. Liu Q, et al. 1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice. Molecules. 2015 Dec 4;20(12):21700-14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA